AUS
NZ
UK
CA
USA
IND
Highlights:
Goldman Sachs identifies Moderna as a top growth stock, with a growth investment ratio of 196% and 39 hedge fund holders.
Moderna's significant investments in new vaccines, such as a norovirus treatment, have resulted in increased R&D expenses and a loss-making bottom line.
Despite losses, Moderna's stock saw a 5% increase after its Q3 results, showing promise for long-term growth.
Description:
Goldman Sachs has highlighted Moderna, Inc. (NASDAQ:MRNA) as one of the top growth stocks, noting its strong growth investment ratio of 196%. The company, known for its mRNA technology, has been aggressively investing in the development of new vaccines, including a norovirus treatment. These investments have driven a rise in research and development expenses, leading to a loss-making bottom line in the short term. However, Moderna's focus on expanding its portfolio of vaccines has been met with a positive response, as evidenced by a 5% increase in its stock price following the release of its Q3 results.
In the broader market context, Goldman Sachs has revised its long-term forecast for the U.S. stock market, pointing out that market concentration—driven largely by artificial intelligence (AI) stocks—has influenced recent performance. The firm suggests that large-cap stocks, particularly those with significant AI exposure, have dominated market returns. For instance, leading tech companies that heavily invest in AI have seen substantial gains. Goldman Sachs has also noted a trend in the performance of the equal-weighted S&P index, predicting it will outperform the market cap-weighted S&P index over the next decade.
The report draws parallels to the dotcom boom, where an initial underperformance of the equal-weighted index was followed by a reversal and outperformance. Goldman Sachs suggests that this pattern, seen during the 1990s and early 2000s, is likely to repeat, with the equal-weighted index showing strength in the coming years as AI-driven mega-cap stocks eventually face a correction. This scenario positions Moderna, with its growing portfolio and ongoing innovations, as a potential candidate for future long-term growth, despite the current volatility in its financial performance.
